Demand Soars for Weight-Loss Drugs Despite High Costs
<div class=" fuertes-blockutinional
Advertisement
Prescription fills for blockbuster weight-loss drugs more than doubled in 2024 even as many Americans struggle to afford the treatments.
Novo Nordisk's Wegovy and Eli Lilly's Zepbound are generating massive interest in the drug market – and prompting intensifying questions about affordability and insurance coverage.
Should access to potentially life-changing weight loss drugs be limited by affordability?
## Is the Price of Weight Loss Too High?
**Host:** Welcome back to the show. Today we’re discussing the surge in popularity of weight-loss drugs like Wegovy and Zepbound, despite their hefty price tags. Joining us is Dr. Emily Chen, a leading expert in obesity and nutritional health. Dr. Chen, thanks for being here.
**Dr. Chen:** Thank you for having me.
**Host:** We’re seeing prescription fills for these drugs more than double in just this past year. While the results seem promising, many Americans are struggling to afford them. What are your thoughts on this growing trend and the potential ethical dilemma it presents?
